For Prelims: Ebola Virus Disease (EVD), Clinical Trial, mRNA Vaccine, World Health Organization (WHO), Vaccine 1, Vaccine 2, Target Virus, Trial Leader
For Mains: Vaccine diplomacy, Global health security, mRNA platform, India's role in pandemic preparedness, Public-private partnership
Source:
Hindustan
5 facts for one-day exams
SSC, railway, police and teaching exams ask direct questions like these.
- WHO approved clinical trials for two new Ebola vaccines.
- One vaccine is co-developed by Oxford University and Serum Institute of India.
- The other vaccine is Moderna's mRNA-1469.
- Both vaccines target the Bundibugyo virus strain.
- More than 5,300 people have died in the current Ebola outbreak in Africa.
Why in the news?
The World Health Organization (WHO) has approved clinical trials for two new Ebola vaccines, developed by Oxford University/Serum Institute of India and Moderna, specifically targeting the Bundibugyo virus strain. The trials are being led by DR Congo's National Institute for Biomedical Research to combat the ongoing Ebola outbreak in Africa, which has claimed over 5,300 lives.
Summary
- WHO approved clinical trials for two new Ebola vaccines: one by Oxford University and Serum Institute of India, and the other by Moderna (mRNA-1469).
- Both vaccines target the Bundibugyo virus strain, a specific species of Ebola virus.
- DR Congo's National Institute for Biomedical Research is leading the clinical trial.
- The approval comes amid an Ebola outbreak in Africa that has caused over 5,300 deaths.
Highlights
Two New Vaccines Approved
WHO approved clinical trials for two new Ebola vaccines: one by Oxford/Serum Institute of India, the other by Moderna (mRNA-1469).
Targeting Bundibugyo Strain
Both vaccines are specifically designed for the Bundibugyo virus, a strain of Ebola causing the current outbreak.
Africa Outbreak Context
The approval comes as Africa faces an Ebola outbreak that has killed over 5,300 people.
Key Analysis and Impact
The approval of two new vaccines, including one from India's Serum Institute (the world's largest vaccine manufacturer by volume), signals a strategic shift towards developing strain-specific vaccines. Moderna's mRNA-1469 leverages the same mRNA platform used for COVID-19 vaccines, which allows rapid adaptation to viral mutations. This partnership between Oxford University and Serum Institute of India also strengthens India's role in global health security and vaccine diplomacy.
Way Forward
The clinical trials will be conducted in DR Congo under the leadership of its National Institute for Biomedical Research. If successful, these vaccines could be deployed to control the current outbreak and serve as a model for rapid response to future viral hemorrhagic fever outbreaks. The WHO's role as a coordinator in emergency vaccine development highlights its importance in pandemic preparedness.
Background GK
Textbook concepts you need to understand this news
- Ebola Virus Disease (EVD)
- A severe, often fatal illness in humans caused by the Ebola virus, transmitted through direct contact with bodily fluids. Symptoms include fever, severe headache, and internal bleeding.
- Clinical Trial
- A research study in human volunteers to evaluate the safety, efficacy, and side effects of a new medical treatment or vaccine before it is approved for public use.
- mRNA Vaccine
- A type of vaccine that uses messenger RNA to instruct cells to produce a protein that triggers an immune response, without using the live virus. Moderna's COVID-19 vaccine was the first widely used mRNA vaccine.
- World Health Organization (WHO)
- A specialized agency of the United Nations responsible for international public health, headquartered in Geneva, Switzerland. Its current Director-General is Tedros Adhanom Ghebreyesus.
Facts to remember
Tap a card to see the answer. Try to recall it first.
How exams will ask this
- Data: Over 5,300 deaths in the current Ebola outbreak
- Nodal Body: World Health Organization (WHO)
Don't make this mistake!
Examiners may ask about the 'Bundibugyo virus' and swap it with other Ebola strains (Zaire, Sudan) or other hemorrhagic fevers (Marburg, Lassa). Remember: Bundibugyo is the specific strain targeted by these vaccines. Also, don't confuse Serum Institute of India (Pune-based) with Bharat Biotech or other Indian vaccine makers.
Write these in mains answers
- Vaccine diplomacy, Global health security, mRNA platform, India's role in pandemic preparedness, Public-private partnership
Stuck? Get it in one tap
The World Health Organization (WHO) said yes to testing two new vaccines against Ebola, a deadly virus. One vaccine was made by Oxford University and India's Serum Institute together. The other is by Moderna, the company that made a COVID vaccine. Both are designed for a specific type of Ebola called Bundibugyo. The tests will happen in DR Congo, where an outbreak has already killed over 5,300 people.
- WHO approved clinical trials for two new Ebola vaccines.
- One vaccine is co-developed by Oxford University and Serum Institute of India.
- The other vaccine is Moderna's mRNA-1469.
- Both vaccines target the Bundibugyo virus strain.
- More than 5,300 people have died in the current Ebola outbreak in Africa.
- Science and Technology: Biotechnology and vaccines
- International Relations: Global health governance and WHO
Related concepts: Ebola Virus Disease (EVD), Clinical Trial, mRNA Vaccine, World Health Organization (WHO)
Practice questions
Pick an answer, then read the explanation.
- Q1Easy
Which organization approved the clinical trials for the two new Ebola vaccines?
Explanation: The WHO is the United Nations agency responsible for global public health. It approved the clinical trials for the two new Ebola vaccines. UNICEF focuses on children's welfare, IMF on financial stability, and World Bank on economic development, not vaccine approvals.
- Q2Hard
Consider the following statements regarding the new Ebola vaccines approved by WHO:
- 1.One of the vaccines is co-developed by Oxford University and Serum Institute of India.
- 2.The vaccines target the Zaire strain of the Ebola virus.
- 3.Moderna's mRNA-1469 is one of the approved vaccines.
Which of the statements given above is/are correct?
Explanation: Statement 1 is correct: the first vaccine is co-developed by Oxford University and Serum Institute of India. Statement 2 is incorrect: the vaccines target the Bundibugyo virus strain, not Zaire. Statement 3 is correct: Moderna's mRNA-1469 is the second approved vaccine. Hence option C is correct.
- Q3Medium
How many deaths have been reported in the ongoing Ebola outbreak in Africa according to the news?
Explanation: Over 5,300 people have died in the Ebola outbreak. Hence 5,300 is the correct number.
- Q4Medium
Which institution is leading the clinical trial for the new Ebola vaccines?
Explanation: DR Congo's National Institute for Biomedical Research is leading the clinical trial. Oxford University and Serum Institute are co-developers of one vaccine, and Moderna is the developer of the other, but none of them lead the trial.
Frequently asked questions
1. Which organization approved the clinical trials for the new Ebola vaccines?
The World Health Organization (WHO) approved the clinical trials for the two new Ebola vaccines.
2. Who developed the two new Ebola vaccines?
The first vaccine was co-developed by Oxford University and Serum Institute of India. The second vaccine is Moderna's mRNA-1469.
3. Which Ebola virus strain do the new vaccines target?
Both vaccines specifically target the Bundibugyo virus strain.
4. Which institution is leading the clinical trial for the new Ebola vaccines?
DR Congo's National Institute for Biomedical Research is leading the clinical trial.
All sources
- Original4 November 2026 · Read story
